Mga Batayang Estadistika
| LEI | 5493001QFG6NIN60NK56 |
| CIK | 1169987 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to HTG Molecular Diagnostics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2023 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commis |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2023 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commis |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2023 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commis |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2023 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| May 10, 2023 |
HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights HTG Molecular Diagnostics, Inc. 3430 E. Global Loop, Tucson, AZ 85706 1-877-289-2615 www.htgmolecular.com Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights TUCSON, Ariz., May 10, 2023 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today repo |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2023 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commis |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2023 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Comm |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37369 HTG Molecular D |
|
| March 30, 2023 |
HTG Molecular Diagnostics, Inc. Amended and Restated 2014 Employee Stock Purchase Plan. Exhibit 10.9 HTG Molecular Diagnostics, Inc. Amended and Restated 2014 Employee Stock Purchase Plan Adopted by the Board of Directors: May 20, 2021 Approved by the Stockholders: August 18, 2021 In accordance with Section 11(a), the maximum number of securities subject to the Plan pursuant to Section 3(a) have been updated to give effect to a proportional adjustment approved by the Board in connect |
|
| March 30, 2023 |
Exhibit 4.12 DESCRIPTION OF COMMON STOCK The following summary describes the material terms of the common stock, par value $0.001 per share, of HTG Molecular Diagnostics, Inc. (“we,” “us” and “our”). The description of common stock is qualified by reference to our amended and restated certificate of incorporation and our amended and restated bylaws, which are incorporated by reference as exhibits |
|
| March 30, 2023 |
HTG Molecular Diagnostics, Inc. Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.14 HTG MOLECULAR DIAGNOSTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of HTG Molecular Diagnostics, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries and who is designated by the Board or the Compensation Committee of the Board as eligible to receive compen |
|
| March 30, 2023 |
HTG Molecular Diagnostics, Inc. 2021 Inducement Plan. Exhibit 10.10 HTG Molecular Diagnostics, Inc. 2021 Inducement Plan Adopted by the Board of Directors: July 1, 2021 Amended by the Board of Directors: July 6, 2021 In accordance with Section 6(a), the maximum number of shares of Common Stock subject to the Plan pursuant to Section 2(a) have been updated to give effect to a proportional adjustment approved by the Board in connection with the 1-for-1 |
|
| March 30, 2023 |
HTG Molecular Diagnostics, Inc. 2020 Equity Incentive Plan. Exhibit 10.6 HTG Molecular Diagnostics, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: June 24, 2020 Approved by the Stockholders: August 19, 2020 In accordance with Section 6(a), (i) the maximum number of shares of Common Stock subject to the Plan pursuant to Section 2(a) and (ii) the maximum number of shares that may be issued pursuant to the exercise of Incentive Stock Optio |
|
| February 13, 2023 |
HTGM / HTG Molecular Diagnostics Inc / LYTTON LAURENCE W Passive Investment SC 13G/A 1 htg13ga3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H203 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 10, 2023 |
HTGM / HTG Molecular Diagnostics Inc / Samjo Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 3, 2023 |
HTGM / HTG Molecular Diagnostics Inc / Cowen Prime Advisors LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 2, 2023 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| January 6, 2023 |
HTG Molecular Diagnostics, Inc. 3430 E. Global Loop, Tucson, AZ 85706 1-877-289-2615 www.htgmolecular.com Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Announces Certain Preliminary 2022 Unaudited Financial Results Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., January 6, 2023 - HTG Molecular Diagnostics, Inc. |
|
| January 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 6, 2023 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Com |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 29, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| December 23, 2022 |
Exhibit 4.4 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT HTG Molecular Diagnostics, Inc. Warrant Shares: Initial Exercise Date: December 23, 2022 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| December 23, 2022 |
HTG Molecular Diagnostics Announces Pricing of a $10 Million Public Offering HTG Molecular Diagnostics, Inc. 3430 E. Global Loop, Tucson, AZ 85706 1-877-289-2615 www.htgmolecular.com Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Announces Pricing of a $10 Million Public Offering TUCSON, Ariz., December 21, 2022 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide |
|
| December 23, 2022 |
Exhibit 4.2 SERIES A-2 COMMON STOCK PURCHASE WARRANT HTG Molecular Diagnostics, Inc. Warrant Shares: [] Initial Exercise Date: December 23, 2022 THIS SERIES A-2 COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 21, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| December 23, 2022 |
HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering HTG Molecular Diagnostics, Inc. 3430 E. Global Loop, Tucson, AZ 85706 1-877-289-2615 www.htgmolecular.com Exhibit 99.2 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Announces Closing of a $10 Million Public Offering TUCSON, Ariz., December 23, 2022 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide |
|
| December 23, 2022 |
Exhibit 4.1 SERIES A-1 COMMON STOCK PURCHASE WARRANT HTG Molecular Diagnostics, Inc. Warrant Shares: [] Initial Exercise Date: December 23, 2022 THIS SERIES A-1 COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| December 23, 2022 |
Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HTG Molecular Diagnostics, Inc. Warrant Shares: [] Initial Exercise Date: December 23, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| December 22, 2022 |
As filed with the Securities and Exchange Commission on December 21, 2022 POS EX As filed with the Securities and Exchange Commission on December 21, 2022 Registration No. |
|
| December 22, 2022 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-268681 PROSPECTUS 102,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,188,322 Shares of Common Stock Series A-1 Warrants to Purchase up to 1,290,322 Shares of Common Stock Series A-2 Warrants to Purchase up to 1,290,322 Shares of Common Stock Placement Agent Warrants to Purchase up to 38,709 Shares of |
|
| December 21, 2022 |
HTG Molecular Diagnostics, Inc. 3430 E. Global Loop Tucson, AZ 85706 HTG Molecular Diagnostics, Inc. 3430 E. Global Loop Tucson, AZ 85706 December 21, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Benjamin Richie and Abby Adams Re: HTG Molecular Diagnostics, Inc. Registration Statement on Form S-1, as amended (File No. 333-268681) Request for Acceleration of Effective Date Ladi |
|
| December 21, 2022 |
Form of Series A-1 and Series A-2 Warrant to Purchase Common Stock. EX-4.12 Exhibit 4.12 SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT HTG MOLECULAR DIAGNOSTICS, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| December 21, 2022 |
Steven M. Przesmicki +1 858 550 6070 [email protected] December 21, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Benjamin Richie and Abby Adams Re: HTG Molecular Diagnostics, Inc. Registration Statement on Form S-1 Filed December 6, 2022 File No. 333-268681 Ladies and Gentlemen: On behalf of HTG Molecular Diagnostics, I |
|
| December 21, 2022 |
Form of Placement Agent Warrant. EX-4.14 Exhibit 4.14 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT HTG MOLECULAR DIAGNOSTICS, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti |
|
| December 21, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) HTG Molecular Diagnostics, Inc. |
|
| December 21, 2022 |
430 Park Avenue | New York, NY 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC December 21, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: HTG Molecular Diagnostics, Inc. Registration Statement on Form S-1 (Registration No. 333-268681) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursu |
|
| December 21, 2022 |
Form of Securities Purchase Agreement. EX-10.28 Exhibit 10.28 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December , 2022, between HTG Molecular Diagnostics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the t |
|
| December 21, 2022 |
S-1/A Table of Contents Registration No. 333-268681 As filed with the Securities and Exchange Commission on December 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 3826 86-0912294 (State |
|
| December 21, 2022 |
EX-4.2 Exhibit 4.2 HTG INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE LOGO HTG Molecular Diagnostics, Inc. COMMON STOCK CUSIP 40434H 30 2 SEE REVERSE FOR CERTAIN DEFINITIONS THIS CERTIFIES THAT specimen is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE, OF HTG Molecular Diagnostics, Inc. transferable on the books of the Corporation by the holder |
|
| December 21, 2022 |
Form of Pre-Funded Warrant to Purchase Common Stock. EX-4.13 Exhibit 4.13 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HTG MOLECULAR DIAGNOSTICS, INC. Warrant Shares: Initial Exercise Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| December 20, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HTG Molecular Diagnostics, INC. HTG Molecular Diagnostics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: First: The name of this corporation is HTG Molecular Diagnostics, Inc., t |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| December 20, 2022 |
CORRESP 1 filename1.htm Steven M. Przesmicki +1 858 550 6070 [email protected] December 20, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Benjamin Richie and Abby Adams Re: HTG Molecular Diagnostics, Inc. Registration Statement on Form S-1 Filed December 6, 2022 File No. 333-268681 Ladies and Gentlemen: On behalf of HTG |
|
| December 12, 2022 |
Corporate Overview December 2022 Exhibit 99.1 Forward-looking Statements and Other Information This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, including statements regarding: the potential of HTG Molecular Diagnostics, Inc |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 12, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 2)1 HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 40434H203 (CUSIP Number) Milton C. Ault, |
|
| December 6, 2022 |
Power of Attorney. Reference is made to the signature page hereto. S-1 Table of Contents Registration No. 333- As filed with the Securities and Exchange Commission on December 6, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 3826 86-0912294 (State or other jurisdiction of in |
|
| December 6, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) HTG Molecular Diagnostics, Inc. |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 1)1 HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 40434H203 (CUSIP Number) Milton C, Ault, |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 29, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 18, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| November 10, 2022 |
Exhibit 10.2 SECOND Amendment to Loan and security agreement THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into this September 8, 2022, by and between SILICON VALLEY BANK, a California corporation (?Bank?) and HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (?Borrower?) whose address is 3400 E Global Loop, Suite 100, Tucson, AZ 85706. Recitals A. Bank a |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| November 10, 2022 |
HTG Molecular Diagnostics Reports Third Quarter 2022 Results HTG Molecular Diagnostics, Inc. 3430 E. Global Loop, Tucson, AZ 85706 1-877-289-2615 www.htgmolecular.com Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Third Quarter 2022 Results TUCSON, Ariz., November 10, 2022 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and a |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| October 31, 2022 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Pro |
|
| October 21, 2022 |
Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock. Exhibit 3.1 HTG MOLECULAR DIAGNOSTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of HTG Molecular Diagnostics, Inc., a Delaware corporation (the ?Corporation?), that the following resolution was duly adopted by the b |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 21, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| October 21, 2022 |
Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this ?Agreement?) is made as of October 21, 2022, by and between the purchaser listed on Exhibit A attached hereto (the ?Purchaser?) and HTG Molecular Diagnostics, Inc., a Delaware corporation (the ?Company?). RECITALS C. The Company desires to sell to the Purchaser, and the Purchaser desires to purchase from the Company, one share of Series |
|
| September 30, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 30, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) ( |
|
| September 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 15, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) ( |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 17, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Com |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 18, 2022 |
Exhibit 3.1 AMENDMENT TO AMENDED AND RESTATED BYLAWS OF HTG MOLECULAR DIAGNOSTICS, INC. The Amended and Restated Bylaws, as amended (the ?Bylaws?), of HTG Molecular Diagnostics, Inc., a Delaware corporation (the ?Company?), are hereby amended as follows, effective as of August 18, 2022. 1. Section 8 of Article III of the Bylaws is hereby amended and restated in its entirety to read as follows: ?Se |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 11, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Com |
|
| August 11, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Second Quarter 2022 Results Call scheduled for today, August 11, 2022, at 4:30 pm ET TUCSON, Ariz., August 11, 2022 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights a |
|
| August 5, 2022 |
HTGM / HTG Molecular Diagnostics Inc / Ault Global Holdings, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 40434H203 (CUSIP Number) Milton C, Ault, |
|
| August 5, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of HTG Molecular Diagnostics, Inc., a Delaware corporatio |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) HTG MOLECULAR DIAGNOSTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 40434H203 (CUSIP Number) July 28, 2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursuant to which |
|
| July 18, 2022 |
Exhibit 10.1 FIRST Amendment to Loan and security agreement THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into this 14th day of July, 2022, by and between SILICON VALLEY BANK, a California corporation (?Bank?) and HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (?Borrower?) whose address is 3400 E Global Loop, Suite 100, Tucson, AZ 85706. Recitals A. Ban |
|
| July 18, 2022 |
HTGM / HTG Molecular Diagnostics Inc / L5 Capital Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H203 (CUSIP Number) July 15. 2022 (Date of |
|
| July 18, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 14, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commi |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?Definiti |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?Definiti |
|
| June 29, 2022 |
HTGM / HTG Molecular Diagnostics Inc / L5 Capital Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No.)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H203 (CUSIP Number) June 28. 2022 (Date of E |
|
| June 29, 2022 |
Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act. EXHIBIT I FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13G (including amendments thereto) with respect to HTG Molecular Diagnostics, Inc. |
|
| June 27, 2022 |
PRE 14A 1 htgm-pre14a20220707.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (a |
|
| June 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 23, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commi |
|
| June 9, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commis |
|
| May 12, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports First Quarter 2022 Results Call scheduled for today, May 12, at 4:30 pm ET TUCSON, Ariz., May 12, 2022 - HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 12, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commis |
|
| April 15, 2022 |
HTG Molecular Diagnostics, Inc. 3430 E. Global Loop Tucson, AZ 85706 HTG Molecular Diagnostics, Inc. 3430 E. Global Loop Tucson, AZ 85706 April 15, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: HTG Molecular Diagnostics, Inc. (the ?Company?) Registration Statement on Form S-3 (File No. 333-264210) Acceleration Request Requested Date: Tuesday, April 19 |
|
| April 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) HTG MOLECULAR DIAGNOSTICS, INC. |
|
| April 8, 2022 |
As filed with the Securities and Exchange Commission on April 8, 2022 S-3 1 d265159ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on April 8, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HTG MOLECULAR DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 86-0912294 (State or other juris |
|
| March 31, 2022 |
HTGM / HTG Molecular Diagnostics Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H203 (CUSIP Number) March 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| March 29, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Full Year 2021 Results Call scheduled for today, March 29, at 4:30 pm ET TUCSON, Ariz., March 29, 2022 - HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its financial results for the year ended |
|
| March 29, 2022 |
Exhibit 4.12 DESCRIPTION OF COMMON STOCK The following summary describes the material terms of the common stock, par value $0.001 per share, of HTG Molecular Diagnostics, Inc. (?we,? ?us? and ?our?). The description of common stock is qualified by reference to our amended and restated certificate of incorporation and our amended and restated bylaws, which are incorporated by reference as exhibits |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K BDO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37369 HTG Molecul |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 29, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Comm |
|
| March 21, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 21, 2022 |
HTG Molecular Diagnostics Announces $7.5 Million Private Placement Exhibit 99.3 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Announces $7.5 Million Private Placement TUCSON, Ariz., March 18, 2022 (Globe Newswire) - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a private placemen |
|
| March 21, 2022 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 21, 2022 |
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 17, 2022 (the ?Effective Date?), between HTG Molecular Diagnostics, Inc. |
|
| March 21, 2022 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 21, 2022 |
EX-4.4 5 htgm-ex4416.htm EX-4.4 Exhibit 4.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 17, 2022, between HTG Molecular Diagnostics, Inc., a Delaware corporation (the “Company”), and each of the purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pur |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Comm |
|
| March 21, 2022 |
Corporate Overview March 2022 Exhibit 99.1 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding the benefits and capabilities of our transcriptome panel and the timing of its commercial launch, possible companion diagnostic and |
|
| February 15, 2022 |
HTGM / HTG Molecular Diagnostics Inc / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H203 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 40434H203 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 11, 2022 |
HTGM / HTG Molecular Diagnostics Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H203 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 9, 2022 |
HTGM / HTG Molecular Diagnostics Inc / Cowen Prime Advisors LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 8, 2022 |
HTGM / HTG Molecular Diagnostics Inc / Samjo Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 31, 2022 |
HTG Molecular Diagnostics, Inc. 3430 E. Global Loop Tucson, AZ 85706 HTG Molecular Diagnostics, Inc. 3430 E. Global Loop Tucson, AZ 85706 January 31, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: HTG Molecular Diagnostics, Inc. (the ?Company?) Registration Statement on Form S-3 (File No. 333-262357) Acceleration Request Requested Date: Wednesday, Fe |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 27, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| January 27, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.11 HTG MOLECULAR DIAGNOSTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF HTG MOLECULAR DIAGNOSTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking asso |
|
| January 27, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.12 HTG MOLECULAR DIAGNOSTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF HTG MOLECULAR DIAGNOSTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking asso |
|
| January 27, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.10 HTG MOLECULAR DIAGNOSTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF HTG MOLECULAR DIAGNOSTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] |
|
| January 27, 2022 |
As filed with the Securities and Exchange Commission on January 27, 2022 Table of Contents As filed with the Securities and Exchange Commission on January 27, 2022 Registration No. |
|
| January 27, 2022 |
Exhibit 4.7 HTG Molecular Diagnostics, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certi |
|
| January 6, 2022 |
EX-99.2 3 htgm-ex9927.htm EX-99.2 Corporate Overview January 2022 Exhibit 99.2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding the benefits and capabilities of our transcriptome panel and the timing of its commercial launc |
|
| January 6, 2022 |
EX-99.1 2 htgm-ex9918.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Announces Certain Preliminary 2021 Unaudited Financial Results Preliminary full year 2021 unaudited revenue of $8.9 million Cash, cash equivalents and short-term marketable securities of $21.9 million as of December 31, 2021 TUCSON, Ariz., January 6, 2022 (Globe Newswire) - HTG Molecular Diagnostics, Inc |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 6, 2022 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Com |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) HTG MOLECULAR DIAGNOSTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 40434H203 (CUSIP Number) December 31, 2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursuant to whi |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2021 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| November 10, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Third Quarter 2021 Results Call scheduled for today, November 10, at 4:30 pm ET TUCSON, Ariz., November 10, 2021 - HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its financial results for the |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| September 29, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2021 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) ( |
|
| September 29, 2021 |
EX-10.2 3 htgm-ex1028.htm EX-10.2 Exhibit 10.2 FOURTH AMENDMENT TO LEASE AGREEMENT SUITE 100 LEASE This fourth Amendment to Lease Agreement (“Amendment”) is dated to be effective as of the 27 day of September, 2021 (“Effective Date”), by and between Pegasus Properties, L.P., a Wisconsin limited partnership (“Lessor”), and HTG Molecular Diagnostics, Inc., a Delaware corporation, formerly known as H |
|
| September 29, 2021 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE AGREEMENT (Suite 300 - Laboratory) This Third Amendment to Lease Agreement (?Amendment?) is dated to be effective as of the 27 day of September 2021 (?Effective Date?), by and between Pegasus Properties, L.P., a Wisconsin limited partnership (?Lessor?), and HTG Molecular Diagnostics, Inc., a Delaware corporation, formerly known as High Throughput Genomics, Inc |
|
| August 20, 2021 |
Exhibit 99.3 HTG Molecular Diagnostics, Inc. RSU Award Grant Notice (2021 Inducement Plan) HTG Molecular Diagnostics, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in t |
|
| August 20, 2021 |
Exhibit 99.1 HTG Molecular Diagnostics, Inc. 2021 Inducement Plan Adopted by the Board of Directors: July 1, 2021 Amended by the Board of Directors: July 6, 2021 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if appl |
|
| August 20, 2021 |
As filed with the Securities and Exchange Commission on August 20, 2021 As filed with the Securities and Exchange Commission on August 20, 2021 Registration No. |
|
| August 20, 2021 |
Exhibit 99.2 HTG Molecular Diagnostics, Inc. Stock Option Grant Notice (2021 Inducement Plan) HTG Molecular Diagnostics, Inc. (the ?Company?), pursuant to its 2021 Inducement Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth here |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 18, 2021 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Com |
|
| August 19, 2021 |
HTG Molecular Diagnostics, Inc. Amended and Restated 2014 Employee Stock Purchase Plan EX-10.1 2 htgm-ex10124.htm EX-10.1 Exhibit 10.1 HTG Molecular Diagnostics, Inc. Amended and Restated 2014 Employee Stock Purchase Plan Adopted by the Board of Directors: May 20, 2021 Approved by the Stockholders: August 18, 2021 1.General; Purpose. (a)The Plan is adopted by the Company as the successor to and replacement of the HTG Molecular Diagnostics, Inc. 2014 Employee Stock Purchase Plan (the |
|
| August 12, 2021 |
EX-99.1 2 htgm-ex9916.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Second Quarter 2021 Results Call scheduled for today, August 12, at 4:30pm ET TUCSON, Ariz., August 12, 2021 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended Ju |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2021 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Com |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 20, 2021 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commi |
|
| July 20, 2021 |
Advancing the Promise of Precision Medicine HTG Molecular Diagnostics Corporate Overview July 2021 Exhibit 99. |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| June 30, 2021 |
HTGM / HTG Molecular Diagnostics Inc / Hewlett Fund LP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) HTG MOLECULAR DIAGNOSTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 40434H203 (CUSIP Number) June 29, 2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursuant to which th |
|
| June 7, 2021 |
HTGM / HTG Molecular Diagnostics Inc / HIRSCHMAN ORIN - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H203 (CUSIP Number) June 3, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed o Rule 13d- |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2021 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commis |
|
| May 13, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports First Quarter 2021 Results and Provides a Corporate Update Call scheduled for today, May 13, at 4:30 pm ET TUCSON, Ariz., May 13, 2021 - HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended Mar |
|
| April 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 5, 2021 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commi |
|
| April 5, 2021 |
HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results EX-99.1 2 htgm-ex9917.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Preliminary First Quarter 2021 Financial Results TUCSON, Ariz., April 5, 2021 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2 |
|
| March 25, 2021 |
Exhibit 10.18 SECOND AMENDMENT TO LEASE AGREEMENT (Suite 300 - Laboratory) This Second Amendment to Lease Agreement (?Amendment?) is dated to be effective as of the 8th day of December, 2020 (?Effective Date?), by and between Pegasus Properties, L.P., a Wisconsin limited partnership (?Lessor?), and HTG Molecular Diagnostics, Inc., a Delaware corporation, formerly known as High Throughput Genomics, |
|
| March 25, 2021 |
HTG Molecular Diagnostics, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-229045 AMENDMENT NO. 2 DATED MARCH 25, 2021 To Prospectus Supplement dated November 14, 2019 (To Prospectus dated February 11, 2019) $3,928,537 HTG Molecular Diagnostics, Inc. Common Stock We previously entered into a certain Controlled Equity OfferingSM Sales Agreement, or Sales Agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, re |
|
| March 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2021 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Comm |
|
| March 25, 2021 |
Exhibit 10.12 HTG MOLECULAR DIAGNOSTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) of HTG Molecular Diagnostics, Inc. (the ?Company?) who is not also serving as an employee of the Company or any of its subsidiaries and who is designated by the Board or the Compensation Committee of the Board as eligible to receive compen |
|
| March 25, 2021 |
Exhibit 4.13 DESCRIPTION OF COMMON STOCK The following summary describes the material terms of the common stock, par value $0.001 per share, of HTG Molecular Diagnostics, Inc. (?we,? ?us? and ?our?). The description of common stock is qualified by reference to our amended and restated certificate of incorporation and our amended and restated bylaws, which are incorporated by reference as exhibits |
|
| March 25, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Full Year 2020 Results Call scheduled for today, March 25, at 4:30pm ET TUCSON, Ariz., March 25, 2021 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the year ended December 31, 2020. Recent Business Highlights |
|
| March 25, 2021 |
Exhibit 4.2 HTG INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE LOGO HTG Molecular Diagnostics, Inc. COMMON STOCK CUSIP 40434H 20 3 SEE REVERSE FOR CERTAIN DEFINITIONS THIS CERTIFIES THAT specimen is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE, OF HTG Molecular Diagnostics, Inc. transferable on the books of the Corporation by the holder hereof |
|
| March 25, 2021 |
Exhibit 10.13 HTG Molecular Diagnostics, Inc. Severance and Change in Control Plan Approved by the Compensation Committee of the Board of Directors on October 12, 2020 Section 1.Introduction. The HTG Molecular Diagnostics, Inc. Severance and Change in Control Plan (the ?Plan?) is hereby established by the Compensation Committee of the Board of Directors of HTG Molecular Diagnostics, Inc. (the ?Com |
|
| March 25, 2021 |
Exhibit 10.20 THIRD AMENDMENT TO LEASE AGREEMENT SUITE 100 LEASE This third Amendment to Lease Agreement (?Amendment?) is dated to be effective as of the 8th of December, 2020 (?Effective Date?), by and between Pegasus Properties, L.P., a Wisconsin limited partnership (?Lessor?), and HTG Molecular Diagnostics, Inc., a Delaware corporation, formerly known as High Throughput Genomics, Inc. (?Lessee? |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37369 HTG Molecular D |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H203 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 40434H203 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40434H203 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 21, 2021 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| January 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2021 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| January 15, 2021 |
As filed with the Securities and Exchange Commission on January 15, 2021 Registration No. |
|
| January 15, 2021 |
HTG Molecular Diagnostics, Inc. 2014 Employee Stock Purchase Plan. Exhibit 99.1 HTG Molecular Diagnostics, Inc. 2014 Employee Stock Purchase Plan Adopted by the Board of Directors: December 2, 2014 Amended by the Board of Directors: April 23, 2015 Approved by the Stockholders: April 24, 2015 1.General; Purpose. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchas |
|
| January 6, 2021 |
Advancing the Promise of Precision Medicine Corporate Overview January 2021 Exhibit 99. |
|
| January 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| January 5, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Announces Certain Preliminary 2020 Unaudited Financial Results Preliminary full year 2020 unaudited revenue of $8.5 million Cash, cash equivalents and short-term marketable securities of $28.7 million as of December 31, 2020 TUCSON, Ariz., January 5, 2021 (Globe Newswire) - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life sci |
|
| January 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| November 19, 2020 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HTG Molecular Diagnostics, INC. HTG Molecular Diagnostics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: First: The name of this corporation is HTG Molecular Diagnostics, Inc., t |
|
| November 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) ( |
|
| November 10, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Third Quarter 2020 Results Call scheduled for today, November 10, at 4:30pm ET TUCSON, Ariz., November 10, 2020 - HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended September 30, 2020. Recent Busin |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2020 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| August 20, 2020 |
As filed with the Securities and Exchange Commission on August 20, 2020 Registration No. |
|
| August 20, 2020 |
Exhibit 99.3 HTG Molecular Diagnostics, Inc. RSU Award Grant Notice (2020 Equity Incentive Plan) HTG Molecular Diagnostics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein an |
|
| August 20, 2020 |
Exhibit 99.2 HTG Molecular Diagnostics, Inc. Stock Option Grant Notice (2020 Equity Incentive Plan) HTG Molecular Diagnostics, Inc. (the “Company”), pursuant to its 2020 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as se |
|
| August 20, 2020 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2020 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| August 20, 2020 |
Exhibit 10.1 HTG Molecular Diagnostics, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: June 24, 2020 Approved by the Stockholders: August 19, 2020 1.General. (a)Successor to and Continuation of 2014 Plan. The Plan is the successor to and continuation of the 2014 Plan. As of the Effective Date, (i) no additional awards may be granted under the 2014 Plan; (ii) the 2014 Plan’s Ava |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 11, 2020 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Com |
|
| August 11, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Second Quarter 2020 Results Call scheduled for today, August 11, at 4:30pm ET TUCSON, Ariz., August 11, 2020 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended June 30, 2020. Recent Accomplishment |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| July 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| July 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| June 26, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 25, 2020 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, S |
|
| June 25, 2020 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated and effective as of June 24, 2020 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree a |
|
| June 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2020 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Comm |
|
| May 27, 2020 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 13, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports First Quarter 2020 Results Call scheduled for today, May 13, at 4:30pm ET TUCSON, Ariz., May 13, 2020 - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2020. “With the COVID-19 pa |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| May 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2020 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Commis |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2020 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Com |
|
| April 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2020 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Comm |
|
| March 27, 2020 |
HTG Molecular Diagnostics, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-229045 AMENDMENT NO. 1 DATED MARCH 27, 2020 To Prospectus Supplement dated November 14, 2019 (To Prospectus dated February 11, 2019) $12,632,239 HTG Molecular Diagnostics, Inc. Common Stock We previously entered into a certain Controlled Equity OfferingSM Sales Agreement, or Sales Agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, r |
|
| March 25, 2020 |
Exhibit 10.34 Execution Version amendment No. 1 to CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of this 25th day of June, 2018, by and among HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (“HTG”), MIDCAP FUNDING IV TRUST, as Agent for the Lenders (in such capacity, together with its succ |
|
| March 25, 2020 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 24, 2020, is entered into by and between HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not oth |
|
| March 25, 2020 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-229045 PROSPECTUS SUPPLEMENT (To Prospectus dated February 11, 2019) HTG Molecular Diagnostics, Inc. Up to $20,000,000 of Shares of Common Stock and 615,384 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $20,000,000 of shares of our common stock, or Purchase Shares, that we may sell to Lincoln Park C |
|
| March 25, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2020 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Comm |
|
| March 25, 2020 |
Exhibit 4.12 DESCRIPTION OF COMMON STOCK The following summary describes the material terms of the common stock, par value $0.001 per share, of HTG Molecular Diagnostics, Inc. (“we,” “us” and “our”). The description of common stock is qualified by reference to our amended and restated certificate of incorporation and our amended and restated bylaws, which are incorporated by reference as exhibits |
|
| March 25, 2020 |
Purchase Agreement, dated as of March 24, 2020, by and between the Company and Lincoln Park. Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of March 24, 2020 (the “Execution Date”), is entered into by and between HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in |
|
| March 25, 2020 |
Exhibit 10.35 Execution Version amendment No. 2 to CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of this 28th day of November, 2018, by and among HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (“HTG”), MIDCAP FUNDING IV TRUST, as Agent for the Lenders (in such capacity, together with its |
|
| March 25, 2020 |
Exhibit 10.33 Execution Version amendment No. 1 to CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of this 28th day of November, 2018, by and among HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (“HTG”), MIDCAP FINANCIAL TRUST, as Agent for the Lenders (in such capacity, together with its successors |
|
| March 25, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Full Year 2019 Results Increased product and product-related services revenue over prior year, benefitting from expanded menu of profiling assays and increased number of customers adopting technology Released new HTG EdgeSeq Reveal data analysis software (version 2.0.0) Call scheduled for today, March 25, at 4:30pm ET TUCSON, Ari |
|
| March 25, 2020 |
HTGM / HTG Molecular Diagnostics, Inc. 10-K - Annual Report - 10-K pa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37369 HTG Molecula |
|
| March 25, 2020 |
Exhibit 10.47 July 28, 2019 Via Email Only ([email protected]) Byron Lawson Re:Employment Terms Dear Byron: On behalf of HTG Molecular Diagnostics, Inc. (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this “Agreement”). This Agreement will become effective upon the date of your acceptance of the Agreement by sig |
|
| March 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2020 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Com |
|
| February 27, 2020 |
HTGM / HTG Molecular Diagnostics, Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H104 (CUSIP Number) February 25, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 27, 2020 |
Exhibit 10.1 Execution Version amendment No. 2 to CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of this 26th day of February, 2020, by and among HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (“HTG”), MIDCAP FINANCIAL TRUST, as Agent for the Lenders (in such capacity, together with its successors a |
|
| February 27, 2020 |
Exhibit 10.2 Execution Version amendment No. 3 to CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of this 26th day of February, 2020, by and among HTG MOLECULAR DIAGNOSTICS, INC., a Delaware corporation (“HTG”), MIDCAP FUNDING IV TRUST, as Agent for the Lenders (in such capacity, together with its s |
|
| February 27, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) ( |
|
| February 26, 2020 |
Exhibit 3.1 HTG MOLECULAR DIAGNOSTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW HTG MOLECULAR DIAGNOSTICS, INC., Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does here |
|
| February 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2020 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) ( |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 40434H104 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 13, 2020 |
HTGM / HTG Molecular Diagnostics, Inc. / Serrado Capital Llc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2020 |
HTGM / HTG Molecular Diagnostics, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 40434H104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 4, 2020 |
HTGM / HTG Molecular Diagnostics, Inc. / Cowen Prime Services LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H104 (CUSIP Number) January 24, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 31, 2020 |
HTGM / HTG Molecular Diagnostics, Inc. / Samjo Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 23, 2020 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| January 17, 2020 |
January 17, 2020 (File No. 333-235961) As filed with the Securities and Exchange Commission on January 17, 2020 Registration No. |
|
| January 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| January 13, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Announces Preliminary 2019 Unaudited Financial Results Preliminary full year 2019 unaudited revenue of $19.2 million Cash and cash equivalents of $33.0 million as of December 31, 2019 TUCSON, Ariz., January 13, 2020 (Globe Newswire) - HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance |
|
| November 22, 2019 |
HTGM / HTG Molecular Diagnostics, Inc. CORRESP - - CORRESP HTG Molecular Diagnostics, Inc. 3430 E. Global Loop Tucson, AZ 85706 November 22, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joseph McCann and Ada Sarmento Re: HTG Molecular Diagnostics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-234173) Acceleration Request Reque |
|
| November 15, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 11, 2019 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation |
|
| November 15, 2019 |
EX-1.1 2 d833388dex11.htm EX-1.1 Exhibit 1.1 HTG MOLECULAR DIAGNOSTICS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement November 14, 2019 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: HTG Molecular Diagnostics, Inc., a Delaware corporation (the “Company”), confirms its agreement under this Sales Agreement (thi |
|
| November 15, 2019 |
HTG Molecular Diagnostics, Inc. Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-229045 PROSPECTUS SUPPLEMENT (To Prospectus dated February 11, 2019) HTG Molecular Diagnostics, Inc. $20,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, $0.001 par valu |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| November 12, 2019 |
Exhibit 10.2 July 28, 2019 Via Email Only ([email protected]) Re:Employment Terms Dear Shaun: On behalf of HTG Molecular Diagnostics, Inc. (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this “Agreement”). This Agreement will become effective upon the date of your acceptance of the Agreement by signing below (t |
|
| November 12, 2019 |
HTGM / HTG Molecular Diagnostics, Inc. CORRESP - - CORRESP Steven M. Przesmicki +1 858 550 6070 [email protected] November 12, 2019 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joseph McCann and Ada Sarmento RE: HTG Molecular Diagnostics, Inc. Registration Statement on Form S-3 Filed October 11, 2019 File No. 333-234173 Ladies and Gentlemen: |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 12, 2019 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (C |
|
| November 12, 2019 |
Amended and Restated Non-employee Director Compensation Policy. Exhibit 10.1 HTG MOLECULAR DIAGNOSTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) of HTG Molecular Diagnostics, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries and who is designated by the Board or the Compensation Committee of the Board as eligible to receive compens |
|
| November 12, 2019 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Third Quarter 2019 Results Product and product-related services revenue increased by 228% and 125% in the three and nine-month periods, respectively, compared to the prior year periods Call scheduled for today, November 12, at 4:30pm ET TUCSON, Ariz., November 12, 2019 - HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (HTG), a diag |
|
| October 11, 2019 |
HTGM / HTG Molecular Diagnostics, Inc. S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on October 11, 2019 Registration No. |
|
| October 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2019 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| September 30, 2019 |
HTGM / HTG Molecular Diagnostics, Inc. / Serrado Capital Llc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 27, 2019 |
HTGM / HTG Molecular Diagnostics, Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H104 (CUSIP Number) September 20, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| September 27, 2019 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 23, 2019 |
HTG Molecular Diagnostics Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 HTG Molecular Diagnostics Announces Proposed Public Offering of Common Stock TUCSON, AZ, September 19, 2019 – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public of |
|
| September 23, 2019 |
EX-99.2 Exhibit 99.2 HTG Molecular Diagnostics Announces Pricing of $20.0 Million Aggregate Financing, Consisting of $16.6 Million Public Offering of Common Stock and $3.5 Million Concurrent Private Placement TUCSON, AZ, September 20, 2019 – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the pricing of an u |
|
| September 23, 2019 |
EX-1.1 Exhibit 1.1 Execution Version HTG MOLECULAR DIAGNOSTICS, INC. 25,476,989 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement September 20, 2019 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereof c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: HTG Molecular Diagnostics, Inc., a Delaware |
|
| September 23, 2019 |
EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HTG MOLECULAR DIAGNOSTICS, INC. Warrant Shares: Initial Exercise Date: , 2019 Issue Date: , 2019 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| September 23, 2019 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this Agreement) is made and entered into as of September 20, 2019 (the Effective Date) by and among HTG Molecular Diagnostics, Inc., a Delaware corporation (the Company), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Sched |
|
| September 23, 2019 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2019 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporati |
|
| September 23, 2019 |
25,476,989 Shares Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-229045 PROSPECTUS SUPPLEMENT (To Prospectus dated February 11, 2019) 25,476,989 Shares Common Stock We are offering 25,476,989 shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “HTGM.” On September 18, 2019, the closing price of our common stock on the Nasdaq Capital Mar |
|
| September 19, 2019 |
EX-99.1 Exhibit 99.1 Unless the context requires otherwise, references to “HTG,” “HTG Molecular Diagnostics,” “we,” “us” and “our” refer to HTG Molecular Diagnostics, Inc. Forward-looking Statements This Exhibit 99.1 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, th |
|
| September 19, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2019 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporati |
|
| September 19, 2019 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 19, 2019 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-229045 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the |
|
| August 20, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2019 HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Co |
|
| August 6, 2019 |
Exhibit 99.1 FOR IMMEDIATE RELEASE HTG Molecular Diagnostics Reports Second Quarter 2019 Results Product and product-related services revenue increased by 119% and 89%, respectively, compared to the three and six-month periods in the prior year Call scheduled for today, August 6, at 4:30pm ET TUCSON, Ariz., August 6, 2019 - HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (HTG), a diagnostic company |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2019 Date of Report (Date of earliest event reported) HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37369 86-0912294 (State or other jurisdiction of incorporation) (Comm |
|
| August 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37369 HTG Molecular Diagnostics, Inc. |
|
| July 2, 2019 |
HTGM / HTG Molecular Diagnostics, Inc. DEFA14A - - DEFA14A DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 2, 2019 |
HTGM / HTG Molecular Diagnostics, Inc. DEF 14A - - DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
